Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Cambridge, UK, 30 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
Completed Covid-19 Research Project Delivers Encouraging Results
The Indian government asked social media platform Twitter to take down dozens of tweets, including some by local lawmakers, that were critical of India’s handling of the coronavirus outbreak, as
China’s leading social video platform selects 7digital to power music in its apps worldwide